Sugi Predict

Sugi Predict / Targets / HRH3

HRH3

Histamine H3 receptor · Q9Y5N1 · HRH3 on Sugi Atlas →

594,790 patent compounds predicted against HRH3, 304,931 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10637 SCHEMBL10637 0.76 20/20
SCHEMBL10636 SCHEMBL10636 0.61 16/20
SCHEMBL9671 SCHEMBL9671 0.60 16/20
SCHEMBL5842 SCHEMBL5842 0.58 16/20
SCHEMBL5536 SCHEMBL5536 0.63 15/20
SCHEMBL10626 SCHEMBL10626 0.63 15/20
SCHEMBL12303 SCHEMBL12303 0.62 15/20
SCHEMBL13052 SCHEMBL13052 0.56 15/20
Cyclomethycaine Cyclomethycaine (SCHEMBL25345) 0.49 15/20
Cyclomethycaine Cyclomethycaine (SCHEMBL25346) 0.49 15/20
SCHEMBL10149 SCHEMBL10149 0.60 14/20
SCHEMBL10150 SCHEMBL10150 0.60 14/20
SCHEMBL12669 SCHEMBL12669 0.44 13/20
Azelastine Azelastine (SCHEMBL4239) 1.00 12/20
Azelastine Azelastine (SCHEMBL4240) 1.00 12/20
Azelastine Azelastine (SCHEMBL36770) 0.98 12/20
Azelastine Azelastine (SCHEMBL36771) 0.98 12/20
SCHEMBL6137 SCHEMBL6137 0.66 12/20
SCHEMBL10308 SCHEMBL10308 0.66 12/20
SCHEMBL10638 SCHEMBL10638 0.61 12/20

Clinical trials — most relevant to HRH3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia PHASE4COMPLETED
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma PHASE3COMPLETED
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists PHASE3COMPLETED
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines PHASE3RECRUITING
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria PHASE3UNKNOWN
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. PHASE3NOT_YET_RECRUITING
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines PHASE2COMPLETED
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis PHASE2UNKNOWN
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria PHASE2NOT_YET_RECRUITING
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors PHASE2RECRUITING
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge PHASE2COMPLETED
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) PHASE2COMPLETED
A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria PHASE2UNKNOWN
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. PHASE2RECRUITING
Effects of Betahistine Hydrochloride in Overweight Women PHASE1COMPLETED
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration PHASE1COMPLETED
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects PHASE1COMPLETED
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases PHASE1COMPLETED
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases PHASE1COMPLETED
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors PHASE1RECRUITING
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors PHASE1UNKNOWN
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients nanCOMPLETED
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy nanCOMPLETED
Investigation of the Pruritogens of Liver-related Diseases nanUNKNOWN
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick nanCOMPLETED
Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria. nanUNKNOWN
Histamine Pharmacogenetics in Children With Atopic Dermatitis nanCOMPLETED
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HRH3 binder may also engage these)

ProteinNameSimilarity
P58406 — 1.000 P58406 →
Q9QYN8 — 1.000 Q9QYN8 →
Q9JI35 — 1.000 Q9JI35 →
CCKBR Gastrin/cholecystokinin type B receptor 0.943 landscape →
P30552 — 0.940 P30552 →
P46627 — 0.940 P46627 →
P30553 — 0.938 P30553 →
A0A287A2K5 — 0.938 A0A287A2K5 →
P79266 — 0.937 P79266 →
P30796 — 0.933 P30796 →
P56481 — 0.932 P56481 →
EDNRB Endothelin receptor type B 0.928 landscape →
Q9N0W7 — 0.926 Q9N0W7 →
P33533 — 0.924 P33533 →
Q9BGL8 — 0.922 Q9BGL8 →
P32300 — 0.920 P32300 →
P51651 — 0.920 P51651 →
P48302 — 0.920 P48302 →
P56497 — 0.920 P56497 →
OPRD1 Delta-type opioid receptor 0.919 landscape →
O62709 — 0.919 O62709 →
GPR6 G-protein coupled receptor 6 0.918 landscape →
P35463 — 0.918 P35463 →
MLNR Motilin receptor 0.917 landscape →
P30098 — 0.915 P30098 →
Q58CT4 — 0.914 Q58CT4 →
P28088 — 0.914 P28088 →
P21451 — 0.914 P21451 →
Q6YNI2 — 0.912 Q6YNI2 →
O97512 — 0.908 O97512 →